Lester Rachael 4

4 · CytomX Therapeutics, Inc. · Filed Feb 4, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

CytomX (CTMX) Chief Business Officer Rachael Lester Receives Award

What Happened

Rachael Lester, Chief Business Officer of CytomX Therapeutics (CTMX), received equity awards on Feb 2, 2026 totaling 120,000 shares at $0.00 per share. The filing shows three grant lines: 20,000 restricted stock units (RSUs), a 50,000-share derivative award, and a 50,000-share derivative award — totaling 120,000 shares granted (all recorded as Code A — Award/Grant).
These awards are not purchases or sales — they are compensation grants. No cash changed hands on grant; value will depend on future vesting and stock price.

Key Details

Transaction date and price: 2026-02-02, $0.00 per share (grant).
Grant breakdown (per filing/footnotes): 20,000 RSUs; a 50,000-share award that includes equity subject to monthly vesting; and a 50,000-share performance-based award. Total = 120,000 shares.
Vesting/conditions (per footnotes):
- F1: RSUs — 1/3 vest annually on March 15, starting March 15, 2027, subject to continued service.
- F3: Option-like award — 1/48th vests monthly beginning Feb 2, 2026; fully vested after 4 years, subject to continued service.
- F4: PSUs — each PSU vests (and becomes payable) 1/3 upon achievement of each of three clinical milestones, subject to continued service.
- F2 notes one of the grant components “includes 20,000 RSUs” as described in the filing.
Shares owned after transaction: not specified in the provided excerpt.
Filing timeliness: Form 4 was filed Feb 4, 2026 for a Feb 2, 2026 grant — appears timely (Form 4 is due within two business days).

Context

These are awards/long-term compensation, not open-market purchases or immediate sales. The option-style award vests over four years; the PSUs depend on clinical milestones, so actual shares received will depend on service and future milestone achievement. Such grants are common for executive compensation and do not by themselves indicate buying or selling sentiment.

Form 4

Period: 2026-02-02

Chief Business Officer

Transactions

Award
Common Stock
[F1][F2]
2026-02-02+20,000→ 20,000 total
Award
Stock Option (Right to Buy)
[F3]
2026-02-02+50,000→ 50,000 total
Exercise: $6.09Exp: 2036-02-01→ Common Stock (50,000 underlying)
Award
Performance Stock Units (PSUs)
[F4]
2026-02-02+50,000→ 50,000 total
→ Common Stock (50,000 underlying)

Footnotes (4)

[F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date.
[F2]Includes 20,000 RSUs.
[F3]1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
[F4]Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.

Signature

/s/ Christopher Ogden, as Attorney-in-Fact for Rachael Lester|2026-02-04

1 file